Medtronic secures ce mark for minimed™ 780g system for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes

Galway, ireland , july 21, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in medical technology, today announced ce (conformitÉ europÉenne) mark in europe to expand indications of the minimed™ 780g system for use by individuals aged 2 years and older, during pregnancy, as well as type 2 insulin-requiring diabetes. to gain ce mark for this expansion of indications, published clinical data in 2–6-year-olds, pregnant women, and people living with type 2 diabetes was reviewed.
MDT Ratings Summary
MDT Quant Ranking